ArticleTranslational andrology and urology2026
Radiomics and deep learning fusion model based on multiphasic CT for predicting HER2 expression status in bladder urothelial carcinoma: a multicenter study.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human epidermal growth factor receptor 2 (HER2) overexpression is a key therapeutic target for novel antibody-drug conjugates (ADCs) like disitamab vedotin (RC48) in bladder urothelial carcinoma (BLCA), but immunohistochemistry-based assessment is limited by intratumoral heterogeneity and sampling bias. A noninvasive and reliable imaging-based approach is therefore urgently needed. Therefore, this study aimed to construct a noninvasive, imaging-based multimodal model for predicting HER2 expression status in BLCA using tri-phasic CT. Methods: A total of 411 patients from three institutions (2021-2024) who underwent tri-phasic contrast-enhanced computed tomography (CT) and HER2 immunohistochemistry (IHC) were included. Patients were classified as HER2-positive (IHC 2+/3+) or negative (IHC 0/1+) based on therapeutic criteria for ADCs. Patients were divided into training, internal validation, and external validation cohorts. Radiomics models, 2.5D and 3D ResNet50 deep learning models, a clinical model, and a multimodal fusion model were developed. Model performance was evaluated using receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis. Results: Tumor architecture (sessile pattern), hydronephrosis, pelvic pain, and radiological lymph node status were identified as independent predictors of HER2 positivity. The 2.5D ResNet50 model achieved an external area under the curve (AUC) of 0.827, significantly outperforming the 3D model (AUC =0.608). The multimodal fusion model showed the best performance, with AUCs of 0.960, 0.908, and 0.873 in the training, internal validation, and external validation cohorts, respectively. In the external cohort, accuracy, sensitivity, and specificity were 0.819, 0.857, and 0.784. The multimodal model significantly outperformed all single-modality models. Conclusions: A tri-phasic CT-based multimodal model enables noninvasive assessment of HER2 expression status in BLCA, providing a promising tool for selection of patients likely to benefit from ADC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.